Mwandishi:
Mhariri:
ULY CLINIC
Dkt. Benjamin L, MD
17 Machi 2021 20:17:29
Fluconazole na ujauzito
Ingawa taarifa zipo chache, matumizi ya fluconazole kipindi cha kwanza cha ujauzito huonekana kuongeza hatari ya kuzaa watoto wenye madhaifu ya kiuumbaji endapo dozi endelevu ya gramu 400 kwa siku au au zaidi itatumika. Madhaifu ya kiuumbaji hufanana nay ale ya Antley-Bixler syndrome. Mwandishi anaelezea kuwa dozi ndogo huwa haina madhara, kama ile inayotumika kutibu fangasi ukeni. Endapo dawa hii ni lazima kutumika katika matibabu ya maambukizi ya fangasi katika kipindi cha kwanza cha ujauzito, mama mjamzito anatakiwa kuelezwa kuhusu hatari ya kupata mtoto mwenye madhaifu ya kiuumbaji.
Ushauri dhidi ya matumizi kwa mama mjamzito
Taarifa za binadamu (wanyama) zinaonyesha hatari ya kupata madhara kwa kichanga tumboni endpo itatumika zaidi ya dozi ya miligramu zaidi ya 399 kwa siku
Taarifa za binadamu (wanyama) zinaonyesha hatari ya kupata madhara kwa kichanga tumboni endpo itatumika zaidi ya dozi ya miligramu zaidi ya 399 kwa siku, ina maanisha nini?
Taarifa za matumizi ya dawa hii au zile zilizo kundi moja na hii au zile zinazofanana namna zinavyofanya kazi na hii kwa binadamu na wanyama wajawazito , imeonekana kuwa sumu kwenye uumbaji wa kichanga tumboni kwa na kusababisha madhaifu ya uumbaji, ukuaji, viungo vya mwili, ufanyaji kazi wa viungo, tabia au kusababisha kifo cha kichanga au kijusi tumboni katika kipindi chote cha ujauzito. Hata hivyo hatari inaweza kuvumiliwa endpo shida ya mama inahitaji dawa hii.
Ushauri wa matumizi kwa mama anayenyonyesha
Inapatana na unyonyeshaji
Inapatana na unyonyeshaji, ina maanisha nini?
Kiasi kidogo cha dawa hii kinawezekana kuingia kwenye maziwa ya mama, kiasi hiki hakina mashiko ya kusababisha sumu kwa kichanga anayenyonya. Dawa hii haitarajiwi kusababisha madhara kwa kichanga anayenyonya maziwa ya mama anayetumia dawa hii.
ONYO: Usitumie dawa yoyote bila ushauri wa daktari. Dawa zinaweza kuleta madhara mwilini na pia matumizi ya baadhi ya dawa pasipo ushauri na vipimo husababisha vimelea kuwa sugu dhidi ya dawa hiyo.
ULY clinic inakushauri kuwasiliana na daktari wako unapotaka kuchukua maamuzi yoyote yanayohusu afya yako.
Wasiliana na daktari/Mfamasia wa ULY clinic kwa ushauri na Tiba au kuandikiwa dawa kwa kupiga simu au Kubonyeza Pata tiba chini ya tovuti hii.
Imeboreshwa,
1 Julai 2023 17:21:36
Rejea za mada hii
1. Product information. Diflucan. Pfizer, 2001.
2. Tiboni GM, et al. Teratological interaction between the bis-triazole antifungal agent fluconazole and the anticonvulsant drug phenytoin. Teratology 1999;59:81–7.
3. Lee BE, et al. Congenital malformations in an infant born to a woman treated with fluconazole. Pediatr Infect Dis J 1992;11:1062–4.
4. Pursley TJ, et al. Fluconazole-induced congenital anomalies in three infants. Clin Infect Dis 1996;22:336–40.
5. Aleck KA, Bartley DL. Multiple malformation syndrome following fluconazole use in pregnancy: report of an additional patient. Am J Med Genet 1997;72:253–6.
6. Inman W, et al. Safety of fluconazole in the treatment of vaginal candidiasis. A prescription-event monitoring study, with special reference to the outcome of pregnancy. Eur J Clin Pharmacol 1994;46:115–8.
7. Mastroiacovo P, et al. Prospective assessment of pregnancy outcomes after first-trimester exposure to fluconazole. Am J Obstet Gynecol 1996;175:1645–50.
8. Kremery V Jr, Huttova M, Masar O. Teratogenicity of fluconazole. Pediatr Infect Dis 1996;15:841.
9. Wiesinger EC, et al. Fluconazole in Candida albicans sepsis during pregnancy: case report and review of the literature. Infection 1996;24:263–6.
10. Campomori A, Bonati M. Fluconazole treatment for vulvovaginal candidiasis during pregnancy. Ann Pharmacother 1997;118–9.
11. Wilton LV, et al. The outcomes of pregnancy in women exposed to newly marketed drugs in general practice in England. Br J Obstet Gynaecol 1998;105:882–9.
12. Sanchez JM, Moya G. Fluconazole teratogenicity. Prenat Diagn 1998;18:862–3.
13. Kalish RB, et al. Achalasia with Candida esophagitis during pregnancy. Obstet Gynecol 1999;94:850.
14. Sorensen HT, et al. Risk of malformations and other outcomes in children exposed to fluconazole in utero. Br J Clin Pharmacol 1999;48:234–8.
15. Lopez-Rangel E, Van Allen MI. Prenatal exposure to fluconazole: an identifiable dysmorphic phenotype. Birth Defects Res A Clin Mol Teratol 2005;73:919–23.
16. King CT, et al. Antifungal therapy during pregnancy. Clin Infect Dis 1998;27:1151–60.
17. Bean LM, et al. Intra-amniotic fluconazole therapy for Candida albicans intra-amniotic infection. Obstet Gynecol 2013;121:452–4.
18. Molgaard-Nielsen D, et al. Use of oral fluconazole during pregnancy and the risk of birth defects. N Engl J Med 2013;369:830–9.
19. Schilling CG, et al. Excretion of fluconazole in human breast milk (abstract no. 130). Pharmacotherapy 1993;13:287.
20. Force RW. Fluconazole concentrations in breast milk. Pediatr Infect Dis J 1995;14:235–6.
21. Viscoli C, et al. Fluconazole therapy in an underweight infant. Eur J Clin Microbiol Infect Dis 1989;8:925–6.
22. Wiest DB, et al. Fluconazole in neonatal disseminated candidiasis. Arch Dis Child 1991;66:1002.
23. Gurses N, Kalayci AG. Fluconazole monotherapy for Candidal meningitis in a premature infant. Clin Infect Dis 1996;23:645–6.
24. Bodley V, Powers D. Long-term treatment of a breastfeeding mother with fluconazole-resolved nipple pain caused by yeast: a case study. J Hum Lact 1997;13:307–11.
25. Committee on Drugs, American Academy of Pediatrics. The transfer of drugs and other chemical into human milk. Pediatrics 2001;108:776–89.